共 114 条
[1]
Rosenberg SA(1994)Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 JAMA 271 907-13
[2]
Yang JC(2002)Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma Oncology (Huntingt) 16 4-10
[3]
Topalian SL(2003)Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way Am J Clin Dermatol 4 333-46
[4]
Dutcher J(1995)Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 688-96
[5]
Agarwala S(1999)High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 2105-16
[6]
Fyfe G(2000)High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update Cancer J Sci Am 6 S11-4
[7]
Fisher RI(2000)Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma Cancer J Sci Am 6 S55-7
[8]
Rosenberg SA(1998)Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response Ann Surg 228 307-19
[9]
Sznol M(1986)High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings JAMA 256 3117-24
[10]
Parkinson DR(1986)Clinical effects and toxicity of interleukin-2 in patients with cancer Cancer 58 2764-72